2. Search Result
Search Result
Isoforms Recommended: RORγ
Results for "

RORγ

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-49076
    RORγ inverse agonist 1

    		ROR Cancer
    RORγ inverse agonist 1 is the inverse agonist of RORγ .
    RORγ inverse agonist 1
  • HY-120210
    XY018

    		ROR Inflammation/Immunology Cancer
    XY018 is a potent ROR-γ-selective antagonist. XY018 inhibits ROR-γ constitutive activity in 293T cells with high potency (EC50, 190 nM). XY018 binds to the ROR-γ hydrophobic ligand binding domain (LBD) .
    XY018
  • HY-120785
    SR1555

    		ROR Inflammation/Immunology
    SR1555 is a specific retinoic acid receptor-related orphan nuclear receptor γ (RORγ) inverse agonist with an IC50 value of 1 μM. SR1555 not only inhibits TH17 cell development and function but also increases the frequency of T regulatory cells, as well as inhibits the expression of IL-17. SR1555 can be used for researching autoimmune diseases .
    SR1555
  • HY-10626
    T0901317
    30+ Cited Publications

    		 LXR FXR ROR Apoptosis Cardiovascular Disease Metabolic Disease Cancer
    T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα . T0901317 activates FXR with an EC50 of 5 μM . T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .
    T0901317
  • HY-169220S
    RORγ/DHODH-IN-1

    		ROR Dihydroorotate Dehydrogenase DNA/RNA Synthesis Isotope-Labeled Compounds Infection
    RORγ/DHODH-IN-1 (compound 1404), a deuterium labeled compound, is a dual RORγ and DHODH inhibitor with IC50 values of 9.7 nM and 100 nM, repaectively. RORγ/DHODH-IN-1 blocks the replication of SARS-CoV-2, HCMV, and non-enveloped DNA virus (HAdV5) .
    RORγ/DHODH-IN-1
  • HY-W545294
    RORγ-IN-2

    		ROR Inflammation/Immunology
    RORγ-IN-2 (Compound 22) is a RORγ inhibitor, with a Ki of 16.6 nM for hRORγ. RORγ-IN-2 can be used for the research of IL-17-dependent autoimmune diseases .
    RORγ-IN-2
  • HY-169222S
    RORγ/DHODH-IN-2

    		Dihydroorotate Dehydrogenase ROR SARS-CoV Infection
    RORγ/DHODH-IN-2 (Compound 1311) is an orally active dual inhibitor of RORγ/DHODH with IC50 values of 11.9 nM and 90 nM, respectively. RORγ/DHODH-IN-2 exhibits antiviral activity by inhibiting the activity of SARS-CoV-2, HCMV, HAdV5, and MPXV, with IC50 values of 27 nM, 20 nM, 9.1 nM, and 1.8 nM, respectively .
    RORγ/DHODH-IN-2
  • HY-155542
    RORγ antagonist 1

    		ROR Cancer
    RORγ antagonist 1 (compound 22), a potent betulinic acid derivative, is an antagonist of RORγ (KD=0.18 μM). RORγ antagonist 1 exhibits anti-proliferative activity in HPAF-II pancreatic cancer xenograft model. RORγ antagonist 1 inhibits RAS/MAPK and AKT/mTORC1 pathway, and induces caspase-dependent apoptosis in pancreatic cancer cells .
    RORγ antagonist 1
  • HY-132900
    RORγ agonist 1

    		ROR Cancer
    RORγ agonist 1 is a potent and orally bioavailable RORγ agonist (EC50 = 21 nM) with antitumor activity.
    RORγ agonist 1
  • HY-129338
    CID 7309015

    		ROR Inflammation/Immunology
    CID 7309015 is an inhibitor of retinoic acid-related orphan receptor gamma (ROR-γ). CID 7309015 can be used for research of inflammation, NF-κB signaling or inflammatory arthritis .
    CID 7309015
  • HY-126037
    (±)-ML 209
    1 Publications Verification

    		 ROR Inflammation/Immunology
    (±)-ML 209 (compound 4n), a diphenylpropanamide, is a retinoic acid-related orphan receptor RORγ antagonist with an IC50 of 1.1 μM. (±)-ML 209 inhibits RORγt transcriptional activity with an IC50 of 300 nM in HEK293t cells. (±)-ML 209 inhibits the transcriptional activity of RORγt, but not RORα in cells. (±)-ML 209 selectively inhibits murine Th17 cell differentiation without affecting the differentiation of naïve CD4 + T cells into other lineages, including Th1 and regulatory T cells .
    (±)-ML 209
  • HY-10626R
    T0901317 (Standard)

    		Reference Standards LXR FXR ROR Apoptosis Cardiovascular Disease Metabolic Disease Cancer
    T0901317 (Standard) is the analytical standard of T0901317. This product is intended for research and analytical applications. T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα . T0901317 activates FXR with an EC50 of 5 μM . T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .
    T0901317 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: